Apixaban (Eliquis(R)) was registered also for stroke and systemic embolic events prevention in atrial fibrillation patients by the end of 2012

Abstract

Advertorial. The article brings a summary of clinical experience with apixaban in atrial fibrillation, esepcially results of major clinical trials AVERROES (vs acetylsalicylic acid) and ARISTOTLE (vs. warfarin).

Keywords

• Apixaban
• atrial fibrillation
• thromboembolic events
• stroke
• prevention